Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: heart disease

U.S. FDA Panel Backs Valeant Psoriasis Drug with Risk Program

Toni Clarke  |  

(Reuters)—Valeant Pharmaceuticals International Inc.’s experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory committees but typically…

Why Rheumatologists Should Focus on Patients’ Cardiovascular Health

  |  

Baseball is a great sport. It’s fascinating to watch the evolving duel between pitcher and batter. As the former employs their remarkably powerful and versatile rotator cuff and forearm flexor muscles to hurl blazing pitches, the latter engages their exceptionally honed hand–eye neural link to make contact with the ball. Baseball is the ultimate summertime…

Rheumatologist Amanda Nelson, MD, MSCR, Walks with Patients to Encourage Physical Activity

  |  

“No more excuses.” At least, that’s what Amanda Nelson, MD, MSCR, now tells her patients. As a rheumatologist, assistant professor in the School of Medicine at the University of North Carolina at Chapel Hill (UNC) and clinical researcher at UNC’s onsite Thurston Arthritis Research Center, Dr. Nelson says patients often provide a litany of legitimate—and sometimes…

Tofacitinib Promising for Psoriatic Arthritis & FDA Issues Alert for Warning for Saxagliptin & Alogliptin Diabetes Treatments

  |  

A recent Phase 3 study found tofacitinib safe and effective for treating psoriatic arthritis at both 5 mg and 10 mg doses compared with placebo. And the FDA has added label warnings to saxagliptin and alogliptin for an increased risk of heart failure in individuals taking the drugs, particularly in those with heart and kidney disease…

2015 ACR/ARHP Annual Meeting: Therapies that Target Schnurri-3 Hold Promise for Osteoporosis

  |  

SAN FRANCISCO—The discovery of a promising new target for the treatment of osteoporosis has a beginning to the story that, when it comes to scientific breakthroughs, rings familiar: It started with a disappointment. Researchers in the lab of Laurie H. Glimcher, MD, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College—were in search…

Knowledge of Genetic Risk Doesn’t Prompt Behavior Changes

Kathryn Doyle  |  

(Reuters Health)—Telling patients about their genetic risk for disease doesn’t usually lead to healthy behavior changes, such as eating better or exercising more, according to a new analysis of existing studies. Researchers selected 18 studies that tracked seven potential behavior changes—such as quitting smoking, diet, physical activity and using sun protection—among people who had received…

Respiratory-Related Mortality Higher in Men with RA

Catherine Kolonko  |  

A study that found men with rheumatoid arthritis (RA) died from respiratory-related illness nearly three times as often as the general population could provide insight into possible treatment options and lifestyle changes that would help them live longer. The Study Researchers at the Veterans Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical…

2015 ACR/ARHP Annual Meeting: Genetic Links Emerge in Osteoarthritis

  |  

SAN FRANCISCO—As researchers have delved into the genetics behind osteoarthritis (OA), genes that appear to be players in the disease have emerged, but there have also been curveballs thrown, with expectations not always matching up to the genetic realities, an expert said at the 2015 ACR/ARHP Annual Meeting. The genetic risk of acquiring OA is…

Patients Get Mixed Reactions from Docs over Mail-Ordered Genetic Tests

Andrew M. Seaman  |  

(Reuters Health)—Patients who order direct-to-consumer genetic tests report mixed experiences when they take the results to their doctors, a new study found. About a quarter of people who ordered direct-to-consumer genetic testing from such companies as 23andMe reported discussing the results with their primary care doctors. But nearly one in five were not at all…